| Effects of Exercises on Total Body Health in Children With Acute Lymphoblastic Leukemia (NCT04015882) | Bezmialem Vakif University | 2019-08-01 |
| A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients (NCT03677596) | Pfizer | 2019-07-01 |
| Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (NCT03960840) | Novartis Pharmaceuticals | 2019-06-26 |
| Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) (NCT03904134) | Center for International Blood and Marrow Transplant Research | 2019-06-14 |
| Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab (NCT03982992) | Ludwig-Maximilians - University of Munich | 2019-06-01 |
| Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia (NCT03571321) | University of Chicago | 2019-05-28 |
| Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies (NCT04008251) | Wuhan Sian Medical Technology Co., Ltd | 2019-05-27 |
| Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia (NCT03913559) | St. Jude Children's Research Hospital | 2019-05-14 |
| Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT03318770) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2019-05-10 |
| Nutritional Status in Children With ALL in Guatemala (NCT03471416) | Columbia University | 2019-05-01 |
| CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients (NCT03902197) | Xuanwu Hospital, Beijing | 2019-04-22 |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT03802695) | Orca Biosystems, Inc. | 2019-04-08 |
| Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia (NCT03798509) | Hrain Biotechnology Co., Ltd. | 2019-03-13 |
| CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT (NCT03810196) | Children's Hospital of Philadelphia | 2019-03-01 |
| Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (NCT03792633) | University of Pennsylvania | 2019-01-18 |
| MT2017-45: CAR-T Cell Therapy for Heme Malignancies (NCT03642626) | Masonic Cancer Center, University of Minnesota | 2018-12-18 |
| A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) (NCT03821610) | University of Birmingham | 2018-11-22 |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (NCT03555955) | Jazz Pharmaceuticals | 2018-11-20 |
| Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia (NCT03575325) | H. Lee Moffitt Cancer Center and Research Institute | 2018-10-11 |
| HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation (NCT03655145) | Assistance Publique - Hôpitaux de Paris | 2018-08-01 |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03494569) | City of Hope Medical Center | 2018-07-06 |
| REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia (NCT03742323) | PETHEMA Foundation | 2018-07-01 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (NCT02890758) | Brenda Cooper, MD | 2018-05-22 |
| Pharmacogenomics of Asparaginase Induced Hepatotoxicity (NCT03568266) | University of Southern California | 2018-05-22 |
| International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (NCT03705507) | University of Birmingham | 2018-05-18 |
| Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia (NCT03564678) | M.D. Anderson Cancer Center | 2018-05-17 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (NCT03448393) | National Cancer Institute (NCI) | 2018-03-26 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921) | Fred Hutchinson Cancer Center | 2018-02-23 |
| Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy (NCT03422731) | City of Hope Medical Center | 2018-02-15 |
| Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease (NCT03441061) | M.D. Anderson Cancer Center | 2018-02-15 |
| Anti-mullerian Hormone in Acute Lymphoblastic Leukemia (NCT05793463) | IRCCS Burlo Garofolo | 2018-02-15 |
| Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (NCT03147612) | M.D. Anderson Cancer Center | 2018-02-08 |
| PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia (NCT03429387) | Peter MacCallum Cancer Centre, Australia | 2018-01-08 |
| Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab (NCT03286114) | University of Michigan Rogel Cancer Center | 2017-12-21 |
| Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia (NCT03204916) | Children's Oncology Group | 2017-12-18 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia (NCT03249636) | Assiut University | 2017-12-01 |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia (NCT03263572) | M.D. Anderson Cancer Center | 2017-11-29 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (NCT02999854) | Kiadis Pharma | 2017-11-29 |
| CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma (NCT03298828) | Third Military Medical University | 2017-11-01 |
| Dependence Receptors and Leukemia (NCT03278145) | Hospices Civils de Lyon | 2017-11-01 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034) | Fred Hutchinson Cancer Center | 2017-10-24 |
| Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (NCT03476239) | Amgen | 2017-10-18 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma (NCT03178617) | City of Hope Medical Center | 2017-10-12 |
| Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant (NCT03267186) | Andrew Rezvani | 2017-09-12 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCT03246906) | Fred Hutchinson Cancer Center | 2017-09-11 |
| A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance (NCT03114865) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-09-05 |
| Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase (NCT03267030) | Birgitte Klug Albertsen | 2017-08-23 |
| Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing (NCT03226704) | National Cancer Institute (NCI) | 2017-08-14 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT03007147) | Children's Oncology Group | 2017-08-08 |
| Cognitive Intervention at the End of Therapy for Survivors of Childhood ALL Treated on TOTXVI (NCT03187977) | St. Jude Children's Research Hospital | 2017-08-03 |
| Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group (NCT03141398) | Hamad Medical Corporation | 2017-08-01 |
| Quality of Life in Children With Cancer (NCT03190499) | Cumhuriyet University | 2017-08-01 |
| CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia (NCT03275493) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2017-07-01 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (NCT03195010) | Fred Hutchinson Cancer Center | 2017-06-09 |
| D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia (NCT02744768) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2017-05-31 |
| Phase III B in Acute Lymphoblastic Leukemia (NCT03123939) | Novartis Pharmaceuticals | 2017-04-24 |
| ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 (NCT03286634) | National Hospital Organization Nagoya Medical Center | 2017-04-18 |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (NCT03117751) | St. Jude Children's Research Hospital | 2017-03-29 |
| Effect of Different Exercises on Quality of Life of Leukemia Patients. (NCT03147365) | Children's Cancer Hospital Egypt 57357 | 2017-03-05 |
| Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (NCT03023046) | University of Washington | 2017-02-23 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646) | M.D. Anderson Cancer Center | 2017-01-18 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study (NCT03733249) | Bellicum Pharmaceuticals | 2017-01-01 |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies (NCT02743351) | Fate Therapeutics | 2016-12-20 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773) | University of Arizona | 2016-11-29 |
| Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma (NCT02518750) | St. Jude Children's Research Hospital | 2016-11-23 |
| Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology (NCT02847130) | Children's Oncology Group | 2016-11-21 |
| Thiopurine EnhAnced Maintenance Therapy (NCT02912676) | Kjeld Schmiegelow | 2016-10-01 |
| Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study (NCT02632903) | Children's Hospital of Eastern Ontario | 2016-10-01 |
| Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone (NCT02815059) | University of Utah | 2016-09-28 |
| A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents (NCT02716233) | Assistance Publique - Hôpitaux de Paris | 2016-09-19 |
| Long-Term Follow-up Study for Patients Previously Treated With JCAR015 (NCT02813252) | Juno Therapeutics, a Subsidiary of Celgene | 2016-08-30 |
| Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment (NCT02881086) | Goethe University | 2016-08-01 |
| Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia (NCT02807883) | M.D. Anderson Cancer Center | 2016-08-01 |
| Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic Leukemia (NCT04699162) | Christian Omar Ramos-Peñafiel, MD, PhD | 2016-07-01 |
| Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia (NCT02186860) | Affiliated Hospital to Academy of Military Medical Sciences | 2016-07-01 |
| Personalized NK Cell Therapy in CBT (NCT02727803) | M.D. Anderson Cancer Center | 2016-05-19 |
| Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia (NCT02810223) | Beijing Sanwater Biological Technology Co., Ltd. | 2016-05-01 |
| Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia (NCT04082286) | Great Ormond Street Hospital for Children NHS Foundation Trust | 2016-05-01 |
| Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies (NCT03366324) | Wuhan Sian Medical Technology Co., Ltd | 2016-05-01 |
| Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies (NCT03366350) | Wuhan Sian Medical Technology Co., Ltd | 2016-04-15 |
| CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia (NCT02443831) | University College, London | 2016-04-01 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies (NCT02639559) | Washington University School of Medicine | 2016-03-31 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) (NCT02669264) | ADC Therapeutics S.A. | 2016-03-01 |
| Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (NCT02508038) | University of Wisconsin, Madison | 2016-02-12 |
| Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) (NCT02588092) | ADC Therapeutics S.A. | 2016-02-01 |
| Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I (NCT02553460) | St. Jude Children's Research Hospital | 2016-01-29 |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia (NCT02779283) | OHSU Knight Cancer Institute | 2016-01-13 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies (NCT02529813) | M.D. Anderson Cancer Center | 2015-12-16 |
| CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies (NCT02965092) | Wuhan Sian Medical Technology Co., Ltd | 2015-12-02 |
| Vaccinating Children After Chemotherapy (NCT02447718) | Canadian Immunization Research Network | 2015-11-16 |
| A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase (NCT02369653) | Bristol-Myers Squibb | 2015-10-22 |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children (NCT02646839) | Michael Pulsipher | 2015-10-01 |
| Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (NCT02544438) | BioSight Ltd. | 2015-09-01 |
| Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT02535364) | Juno Therapeutics, a Subsidiary of Celgene | 2015-08-21 |
| Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults (NCT02535806) | Children's Mercy Hospital Kansas City | 2015-07-01 |
| Study of Palbociclib in MLL-rearranged Acute Leukemias (NCT02310243) | University of Ulm | 2015-07-01 |